Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Alan Bash named president of Carvykti at Legend

Plus: CureVac hires Axel Malkomes as CFO; new CEOs at Coya, Libra; and updates from 4BIO, Memo and Alltrna

November 5, 2024 1:40 AM UTC

Legend Biotech Corp. (NASDAQ:LEGN) named Alan Bash president of Carvykti, a newly created role focusing on the BCMA-targeted CAR T cell therapy ciltacabtagene autoleucel. Bash previously held CEO roles at ZielBio Inc. and Checkmate Pharmaceuticals Inc. Carvykti was FDA approved in 2022 to treat relapsed or refractory multiple myeloma and has been dominating the market

CureVac N.V. (NASDAQ:CVAC) hired Axel Malkomes as CFO. Malkomes was CFO of Cardior Pharmaceuticals GmbH and succeeds Pierre Kemula, who left on Oct. 31...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article